Ideaya Biosciences Inc

+0.11 (+0.92%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)573.01M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$6.64 Million
Adjusted EPS-$0.61
See more estimates
10-Day MA$11.68
50-Day MA$12.56
200-Day MA$13.75
See more pivots

Ideaya Biosciences Inc Stock, NASDAQ:IDYA

7000 Shoreline Court, Suite 350, South San Francisco, California 94080-1945
United States of America
Phone: +1.650.443.6209
Number of Employees: 81


IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.